# Orange Book

## 中文解释 / English Explanation

* **定义 / Definition**  
  **中文解释**：Orange Book（橙皮书）是由美国食品药品监督管理局（FDA）发布的一份官方文件，正式名称为《Approved Drug Products with Therapeutic Equivalence Evaluations》（已批准药物产品及其治疗等效性评估）。该文件列出了所有在美国获得批准的药物，并提供了这些药物的专利信息和市场独占权数据。橙皮书的核心概念在于帮助仿制药制造商了解原研药的专利状况，从而决定是否以及何时可以合法地推出仿制药。  
  **English Explanation**: The Orange Book is an official document published by the U.S. Food and Drug Administration (FDA), formally titled "Approved Drug Products with Therapeutic Equivalence Evaluations." It lists all drugs approved for use in the United States and provides information on their patents and market exclusivity. The core concept of the Orange Book is to assist generic drug manufacturers in understanding the patent status of brand-name drugs, thereby determining if and when they can legally launch generic versions.

* **应用 / Application**  
  **中文应用场景**：橙皮书在制药行业中具有重要应用，特别是在仿制药的研发和上市过程中。仿制药制造商通过查阅橙皮书，可以了解原研药的专利到期时间，从而规划仿制药的上市时间。此外，橙皮书还用于解决专利纠纷和确定药物的治疗等效性。需要注意的是，橙皮书的信息可能会因法律诉讼或专利更新而发生变化，因此需要定期更新和核实。  
  **English Application Scenarios**: The Orange Book is widely used in the pharmaceutical industry, particularly in the development and launch of generic drugs. Generic drug manufacturers consult the Orange Book to determine when patents on brand-name drugs expire, allowing them to plan the release of generic versions. Additionally, the Orange Book is used to resolve patent disputes and assess therapeutic equivalence. It is important to note that information in the Orange Book may change due to legal proceedings or patent updates, requiring regular verification.

* **重要性 / Significance**  
  **中文重要性**：从监管角度来看，橙皮书是FDA确保药物市场公平竞争的重要工具；从投资角度来看，它为投资者提供了药物市场独占权的关键信息；从行业角度来看，它促进了仿制药的研发和上市，降低了药品价格。  
  **English Significance**: From a regulatory perspective, the Orange Book is a crucial tool for the FDA to ensure fair competition in the drug market; from an investment perspective, it provides key information on drug market exclusivity; from an industry perspective, it facilitates the development and launch of generic drugs, reducing medication costs.

## 历史典故 / Historical Context

* **起源 / Origin**  
  **中文起源**：橙皮书的起源可以追溯到1984年《药品价格竞争与专利期恢复法案》（Hatch-Waxman Act）的通过。该法案旨在平衡原研药和仿制药之间的利益关系，鼓励仿制药的研发和上市。作为该法案的一部分，FDA开始发布橙皮书，以提供已批准药物的专利和市场独占权信息。自1984年以来，橙皮书已成为美国药品监管体系的重要组成部分。  
  **English Origin**: The origin of the Orange Book dates back to the passage of the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) in 1984. This act aimed to balance interests between brand-name and generic drugs by encouraging generic drug development and approval. As part of this act, the FDA began publishing the Orange Book to provide information on approved drugs' patents and market exclusivity. Since 1984, it has become a cornerstone of U.S. drug regulation.

* **影响 / Impact**  
  **中文影响**：橙皮书的发布极大地推动了美国仿制药行业的发展，使得更多患者能够以更低的价格获得必要的药物治疗。同时，它也促进了原研药与仿制药之间的良性竞争。目前，橙皮书已成为全球许多国家制定类似药物监管政策的参考标准之一。  
  **English Impact**: The publication of the Orange Book has significantly advanced the U.S. generic drug industry, enabling more patients to access essential medications at lower costs. It has also fostered healthy competition between brand-name and generic drugs. Today, it serves as a reference for many countries worldwide in developing similar drug regulatory policies.

## 要点总结 / Takeaway

* **中文**  
  - 核心价值：提供已批准药物的专利和市场独占权信息。
  - 使用场景：仿制药研发、上市规划、专利纠纷解决。
  - 延伸意义：促进药品市场竞争、降低药品价格。

* **English**  
  - Key Point: Provides patent and market exclusivity information for approved drugs.
  - Usage Scenarios: Generic drug development, launch planning, patent dispute resolution.
- Extended Meaning: Promotes competition in drug markets and reduces medication costs.